As part of its advocacy program in Europe, ACRO submits regulatory comments to European officials. This comment letter, submitted by ACRO to EMA in 2017 about Guideline on Strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products can be found below.